KLF4 suppresses anticancer effects of brusatol via transcriptional upregulating NCK2 expression in melanoma
- 6 April 2024
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 223, 116197
Abstract
No abstract availableKeywords
Funding Information
- Dalian Science and Technology Bureau
This publication has 41 references indexed in Scilit:
- ITIH5 as a multifaceted player in pancreatic cancer suppression, impairing tyrosine kinase signaling, cell adhesion and migrationMolecular Oncology, 2024
- Antitumor miR-150-5p and miR-150-3p inhibit cancer cell aggressiveness by targeting SPOCK1 in head and neck squamous cell carcinomaAuris Nasus Larynx, 2018
- Brusatol inhibits growth and induces apoptosis in pancreatic cancer cells via JNK/p38 MAPK/NF-κb/Stat3/Bcl-2 signaling pathwayBiochemical and Biophysical Research Communications, 2017
- KLF4 Initiates Acinar Cell Reprogramming and Is Essential for the Early Stages of Pancreatic CarcinogenesisCancer Cell, 2016
- Brusatol inhibits the response of cultured beta-cells to pro-inflammatory cytokines in vitroBiochemical and Biophysical Research Communications, 2015
- Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patientsClinical & Experimental Metastasis, 2014
- Progression of cutaneous melanoma: implications for treatmentClinical & Experimental Metastasis, 2012
- Krüppel-Like Transcription Factor 4 Contributes to Maintenance of Telomerase Activity in Stem CellsStem Cells, 2010
- Chemotherapy and biologic therapies for melanoma: do they work?Clinics in Dermatology, 2009
- The Nck SH2/SH3 adaptor protein: a regulator of multiple intracellular signal transduction eventsBioEssays, 1998